ABSTRACT
An increase in fish production has consequently brought an increase in infectious diseases in fish farms. The use of chemotherapic drugs is the most effective instrument against common bacterial agents. The number of registered drugs for use in aquaculture is limited and often veterinary practitioners resort to the off-label use of chemotherapic agents authorized for different food-producing animal species. Florfenicol is well known for its outstanding effect against various pathogenic bacteria affecting fish, and therefore, it may be a useful drug for off-label use in aquaculture. The aim of this study was to evaluate the depletion of florfenicol and its major metabolite, florfenicol amine, from the edible tissue of two fish species, rainbow trout and sea bream, following treatment with medicated feed at a dosage of 10 mg kg(-1) of bw day(-1) , for 10 consecutive days. At prefixed time points after the end of administration (0.25, 1, 2, 3, 4, 6, 7, 10, 14 and 21 days after treatment), edible tissues (muscle plus adherent skin) from 15 individuals in each group were collected and analysed by HPLC, to determine concentration of the drug in the tissue. On the basis of the obtained concentrations, withdrawal times of florfenicol in the two species were calculated. The results indicate that a drug withdrawal time of 500 °C-day, as established by Directive 2004/28/EC, for off-label drug use is more than satisfactory to guarantee the healthiness of fish products against the risk of drug residues.
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Drug Residues/pharmacokinetics , Oncorhynchus mykiss/metabolism , Sea Bream/metabolism , Thiamphenicol/analogs & derivatives , Administration, Oral , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/analysis , Aquaculture , Chromatography, High Pressure Liquid/veterinary , Drug Residues/analysis , Meat/analysis , Muscle, Skeletal/metabolism , Species Specificity , Thiamphenicol/administration & dosage , Thiamphenicol/analysis , Thiamphenicol/pharmacokinetics , Time FactorsABSTRACT
Five lactating cows were given benzydamine hydrochloride by rapid intravenous (0.45 mg/kg) and by intramuscular (0.45 and 1.2 mg/kg) injection in a crossover design. The bioavailability, pharmacokinetic parameters and excretion in milk of benzydamine were evaluated. After intravenous administration, the disposition kinetics of benzydamine was best described using a two-compartment open model. Drug disposition and elimination were fast (t1/2 alpha: 11.13 +/- 3.76 min; t1/2 beta: 71.98 +/- 24.75 min; MRT 70.69 +/- 11.97 min). Benzydamine was widely distributed in the body fluids and tissues (Vd(area): 3.549 +/- 1.301 L/kg) and characterized by a high value for body clearance (33.00 +/- 5.54 ml/kg per min). After intramuscular administration the serum concentration-time curves fitted a one-compartment open model. Following a dose of 0.45 mg/kg, the Cmax value was 38.13 +/- 4.2 ng/ml at a tmax of 67.13 +/- 4.00 min; MAT and MRT were 207.33 +/- 22.64 min and 278.01 +/- 12.22 min, respectively. Benzydamine bioavailability was very high (92.07% +/- 7.08%). An increased intramuscular dose (1.2 mg/kg) resulted in longer serum persistence (MRT 420.34 +/- 86.39 min) of the drug, which was also detectable in milk samples collected from both the first and second milking after treatment.
Subject(s)
Benzydamine/pharmacokinetics , Animals , Benzydamine/administration & dosage , Benzydamine/blood , Biological Availability , Cattle , Dose-Response Relationship, Drug , Female , Injections, Intramuscular , Injections, Intravenous , Lactation , Metabolic Clearance Rate , Milk/metabolism , Models, BiologicalABSTRACT
After single po administration of 14C-naphthylcarbamate, liquid scintillation assays evaluated the distribution of carbaryl in rabbit serum, liver, kidneys, small and large intestine, spleen, heart, muscles of the thigh and lungs and its excretion in urine and feces at 2, 4, 6 and 8 h after dosing. At 2 and 8 h radioactivity was not observed in spleen, heart, muscle and lungs, while all other tissues had increased values up to 6 h. The main excretory pathway of carbaryl was the kidneys.
Subject(s)
Body Fluids/chemistry , Carbaryl/pharmacokinetics , Administration, Oral , Animals , Carbaryl/administration & dosage , Carbon Radioisotopes , Female , Pesticide Residues/pharmacokinetics , Rabbits , Tissue DistributionABSTRACT
Plasma concentrations and urinary and fecal excretion of intact dipyridamole were followed in dogs after oral administration of dipyridamole-beta-cyclodextrin complex (dip-beta-CD) (capsules containing 37.5 and 75 mg of active principle), of commercial dipyridamole and of dipyridamole. HCl (tablets and capsules of 75 mg of active principle, respectively), according to a crossover design. Dip-beta-CD afforded significantly shorter lag-times, higher Cmax, smaller interindividual variations of plasma concentrations and greater urinary excretion than the other two preparations, as a consequence of a better bioavailability of the former one. This amelioration seems to be due not only to an increased wettability and water solubility of the product, but also to a finer molecular dispersion in the gastrointestinal fluids which favors the contact of dipyridamole with a greater absorption surface.
